EXEL

$70.091.01%0.70

アフターアワーズ： 70.13+0.04 +0.06%

Exelixis Inc (EXEL)

Date: O: H: L: C: Vol:

前日終値:

$69.39

開ける：

$69.53

24時間の取引高:

4,636,551

相対出来高:

1.81

時価総額：

$17.10B

収益：

$2.38B

当期純損益:

$833.42M

株価収益率:

23.23

EPS:

$3.02

ネットキャッシュフロー:

$917.69M

1W パフォーマンス:

+7.65%

1M パフォーマンス:

+20.04%

6M パフォーマンス:

+60.46%

1Y パフォーマンス:

+81.25%

1日の値動き範囲:

$69.15$72.01

1週間の範囲:

$64.75$72.10

52週間の値動き範囲:

$36.00$72.10

Exelixis Inc（EXEL）会社概要

名前

Exelixis Inc

セクター

Healthcare

産業

Biotechnology

電話

(650) 837-7000

住所

1851 HARBOR BAY PARKWAY, ALAMEDA, CA, USA

職員

1,077

@exelixisinc

次回の収益日

null

最新のSEC提出書

SEC

XでのEXELに関するディスカッション

EXEL と VRTX, REGN, MRNA, ARGX, ONC を比較

株式	時価総額	収益	当期純利益	現金流量	EPS
EXEL Exelixis Inc	$17.10B	$2.32B	$782.57M	$1.17B	$3.02
VRTX Vertex Pharmaceuticals Inc	$140.94B	$12.59B	$4.41B	$3.80B	$16.87
REGN Regeneron Pharmaceuticals Inc	$99.46B	$16.90B	$4.82B	$3.83B	$41.04
MRNA Moderna Inc	$88.17B	$2.23B	-$3.15B	-$1.24B	-$8.15
ARGX Argen X Se Adr	$55.03B	$4.16B	$1.29B	$734.26M	$19.58
ONC Beone Medicines Ltd Adr	$40.86B	$6.13B	$655.71M	$1.33B	$4.48

Exelixis Inc (EXEL) アップグレードとダウングレード

日付	アクション	アナリスト	評価の変更
2026-08-19	開始されました	BMO Capital Markets	Market Perform
2026-08-06	ダウングレード	Leerink Partners	Outperform → Market Perform
2026-06-25	Resumed	Truist	Hold
2026-01-08	ダウングレード	Morgan Stanley	Overweight → Equal-Weight
2026-01-05	ダウングレード	BofA Securities	Neutral → Underperform
2025-11-18	開始されました	Wolfe Research	Peer Perform
2025-11-03	ダウングレード	Guggenheim	Buy → Neutral
2025-10-21	アップグレード	Leerink Partners	Market Perform → Outperform
2025-09-19	Resumed	Barclays	Equal Weight
2025-09-17	Resumed	Barclays	Equal Weight
2025-09-17	開始されました	Goldman	Buy
2025-07-08	ダウングレード	RBC Capital Mkts	Outperform → Sector Perform
2025-06-24	アップグレード	Stephens	Equal-Weight → Overweight
2025-02-24	ダウングレード	Wells Fargo	Overweight → Equal Weight
2025-01-27	アップグレード	Morgan Stanley	Equal-Weight → Overweight
2025-01-24	ダウングレード	Oppenheimer	Outperform → Perform
2024-12-20	ダウングレード	BMO Capital Markets	Outperform → Market Perform
2024-12-17	ダウングレード	BofA Securities	Buy → Neutral
2024-10-16	繰り返されました	RBC Capital Mkts	Outperform
2024-09-19	開始されました	UBS	Neutral
2024-04-11	ダウングレード	Barclays	Overweight → Equal Weight
2023-12-19	開始されました	BTIG Research	Buy
2023-12-15	開始されました	Citigroup	Buy
2023-09-26	開始されました	H.C. Wainwright	Buy
2023-08-22	繰り返されました	Oppenheimer	Outperform
2023-08-08	開始されました	SVB Securities	Market Perform
2023-07-11	Resumed	Morgan Stanley	Equal-Weight
2023-05-10	Resumed	Piper Sandler	Overweight
2023-03-09	開始されました	Wells Fargo	Overweight
2023-01-26	開始されました	Credit Suisse	Outperform
2022-10-18	開始されました	JMP Securities	Mkt Outperform
2022-06-24	開始されました	BMO Capital Markets	Outperform
2021-11-19	開始されました	Piper Sandler	Overweight
2021-11-03	Resumed	Jefferies	Buy
2021-10-07	開始されました	Jefferies	Buy
2021-08-06	繰り返されました	H.C. Wainwright	Buy
2021-06-15	開始されました	H.C. Wainwright	Buy
2021-05-18	Resumed	Goldman	Sell
2021-03-31	開始されました	Credit Suisse	Outperform
2021-03-12	開始されました	Wolfe Research	Outperform
2020-03-04	開始されました	Barclays	Overweight
2020-01-13	開始されました	SunTrust	Buy
2019-11-13	開始されました	BofA/Merrill	Buy
2019-03-18	アップグレード	Morgan Stanley	Underweight → Equal-Weight
2018-09-17	開始されました	Goldman	Neutral
2018-09-10	開始されました	Morgan Stanley	Underweight
2018-05-11	繰り返されました	Needham	Buy
2017-10-17	繰り返されました	Needham	Buy
2017-10-17	繰り返されました	RBC Capital Mkts	Outperform
2017-10-16	繰り返されました	SunTrust	Buy
2017-09-22	ダウングレード	Leerink Partners	Outperform → Mkt Perform
2017-09-15	開始されました	RBC Capital Mkts	Outperform
2017-09-12	繰り返されました	Needham	Buy
2017-07-14	開始されました	SunTrust	Buy
2017-03-31	開始されました	Needham	Buy
2017-03-16	開始されました	Oppenheimer	Perform
2017-02-28	ダウングレード	Stifel	Buy → Hold
2016-11-03	開始されました	Deutsche Bank	Buy
2016-10-10	アップグレード	Piper Jaffray	Neutral → Overweight
2016-09-15	繰り返されました	Stifel	Buy

Exelixis Inc (EXEL) 財務データ

期間	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
期間終了日	2026-01-02	2025-01-03	2023-12-29	2022-12-30	2021-12-31
Revenue USD (M)	2,320.13	2,168.70	1,830.21	1,611.06	987.54
Cost of revenue USD (M)	83.70	76.22	72.55	57.91	36.27
Gross profit USD (M)	-	-	1,757.66	1,553.15	951.27
Research and development USD (M)	825.00	910.41	1,044.07	891.81	547.85
Operating expenses USD (M)	1,447.94	1,564.08	1,586.78	1,351.67	841.21
Operating income USD (M)	872.19	604.62	170.89	201.48	110.06
Income before tax USD (M)	-	-	170.89	201.48	130.84
Income tax expense USD (M)	158.64	160.37	49.76	52.07	19.06
Net income USD (M)	782.57	521.27	207.77	182.28	111.78
Basic EPS USD/shares	2.88	1.80	0.65	0.57	0.36
Diluted EPS USD/shares	2.78	1.76	0.65	0.56	0.35
Basic weighted shares shares (M)	271.57	290.03	318.15	321.53	308.27
Diluted weighted shares shares (M)	281.86	296.13	321.46	324.56	318.00
Selling, general and administrative USD (M)	518.73	492.13	542.71	459.86	293.36

Exelixis Inc (EXEL) インサイダートレーディング

Beckerle Mary CAug 10 '26
Director
取引
Sale
コスト
$53.66
#株式
9,812
値 ($)
526,512
#株式総数
16,079
MARY BECKERLEAug 10 '26
Director
取引
Proposed Sale
コスト
$53.66
#株式
9,812
値 ($)
526,496
#株式総数
0
JACK L WYSZOMIERSKIJun 01 '26
Director
取引
Proposed Sale
コスト
$50.55
#株式
3,925
値 ($)
198,409
#株式総数
0
Eckhardt Sue GailJun 01 '26
Director
取引
Proposed Sale
コスト
$50.87
#株式
9,812
値 ($)
499,136
#株式総数
0
Eckhardt Sue GailJun 01 '26
Director
取引
Sale
コスト
$50.14
#株式
9,812
値 ($)
491,974
#株式総数
16,079
WYSZOMIERSKI JACK LJun 01 '26
Director
取引
Sale
コスト
$50.55
#株式
3,925
値 ($)
198,409
#株式総数
284,384
Aftab DanaMay 26 '26
EVP, Research and Development
取引
Sale
コスト
$50.35
#株式
43,451
値 ($)
2,187,758
#株式総数
594,741
DANA T AFTABMay 26 '26
Officer
取引
Proposed Sale
コスト
$50.35
#株式
43,451
値 ($)
2,187,758
#株式総数
0
PATRICK JOSEPH HALEYMay 20 '26
Officer
取引
Proposed Sale
コスト
$49.81
#株式
32,110
値 ($)
1,599,444
#株式総数
0
Haley Patrick J.May 20 '26
EVP, Commercial
取引
Sale
コスト
$49.81
#株式
32,110
値 ($)
1,599,399
#株式総数
357,638

インサイダートレーディング	関係	日付	取引	コスト	#株式	値 ($)	#株式総数
Beckerle Mary C	Director	Aug 10 '26	Sale	$53.66	9,812	526,512	16,079
MARY BECKERLE	Director	Aug 10 '26	Proposed Sale	$53.66	9,812	526,496	0
JACK L WYSZOMIERSKI	Director	Jun 01 '26	Proposed Sale	$50.55	3,925	198,409	0
Eckhardt Sue Gail	Director	Jun 01 '26	Proposed Sale	$50.87	9,812	499,136	0
Eckhardt Sue Gail	Director	Jun 01 '26	Sale	$50.14	9,812	491,974	16,079
WYSZOMIERSKI JACK L	Director	Jun 01 '26	Sale	$50.55	3,925	198,409	284,384
Aftab Dana	EVP, Research and Development	May 26 '26	Sale	$50.35	43,451	2,187,758	594,741
DANA T AFTAB	Officer	May 26 '26	Proposed Sale	$50.35	43,451	2,187,758	0
PATRICK JOSEPH HALEY	Officer	May 20 '26	Proposed Sale	$49.81	32,110	1,599,444	0
Haley Patrick J.	EVP, Commercial	May 20 '26	Sale	$49.81	32,110	1,599,399	357,638

Exelixis Inc (EXEL) 最新ニュース

Oct 30, 2026

EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales - Zacks Investment Research

Oct 30, 2026

Oct 29, 2026

Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Zacks Investment Research

Oct 29, 2026

Oct 28, 2026

Exelixis stock hits all-time high at 65.62 USD By Investing.com - Investing.com India

Oct 28, 2026

Oct 27, 2026

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research

Oct 27, 2026

Oct 26, 2026

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock - MarketBeat

Oct 26, 2026

Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight - GlobeNewswire Inc.

Oct 26, 2026

Oct 24, 2026

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research

Oct 22, 2026

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Oct 22, 2026

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo! Finance Canada

Oct 22, 2026

Oct 21, 2026

Exelixis Faces A Test Of Its Trimmed Outlook As Street Models Run Above Guidance - Finviz

Oct 21, 2026

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

Oct 21, 2026

Exelixis Inc stock hits all-time high at 63.39 USD By Investing.com - Investing.com Nigeria

Oct 21, 2026

Oct 20, 2026

Exelixis Inc stock hits all-time high at 63.39 USD - Investing.com

Oct 20, 2026

Oct 19, 2026

EXEL Maintained by Citizens -- Price Target Raised to $65.00 - GuruFocus

Oct 19, 2026

Citizens raises Exelixis stock price target to $65 on ESMO data - Investing.com Canada

Oct 19, 2026

Oct 16, 2026

Exelixis, Inc. (1EXEL.MI) stock price, news, quote and history - Yahoo Finance UK

Oct 16, 2026

2 Under-the-Radar Stocks to Buy and Hold - The Motley Fool

Oct 16, 2026

Exelixis, Inc. (0IJO.IL) stock price, news, quote and history - Yahoo Finance UK

Oct 16, 2026

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Zacks Investment Research

Oct 16, 2026

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - BioSpace

Oct 16, 2026

Oct 15, 2026

Exelixis to release Q3FY26 results on Oct 29, 2026 - scanx.trade

Oct 15, 2026

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Yahoo Finance

Oct 15, 2026

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again - Zacks Investment Research

Oct 15, 2026

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Business Wire

Oct 15, 2026

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo! Finance Canada

Oct 15, 2026

Oct 14, 2026

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

Oct 14, 2026

Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance Singapore

Oct 14, 2026

Oct 13, 2026

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - Morningstar

Oct 13, 2026

Oct 12, 2026

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - TradingView

Oct 12, 2026

Exelixis Inc stock hits all-time high at 61.21 USD - Investing.com

Oct 12, 2026

Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com South Africa

Oct 12, 2026

Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com India

Oct 12, 2026

Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capital - ChartMill

Oct 12, 2026

Oct 10, 2026

Virtus NFJ Mid-Cap Value Fund's Exelixis Inc(EXEL) Holding History - GuruFocus

Oct 10, 2026

Oct 09, 2026

Exelixis (NasdaqGS:EXEL) Stock Price - Simply Wall Street

Oct 09, 2026

Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says - marketscreener.com

Oct 09, 2026

RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating - Yahoo Finance

Oct 09, 2026

Oct 08, 2026

EXEL Maintained by RBC Capital -- Price Target Lowered to $45 - GuruFocus

Oct 08, 2026

Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus? - Yahoo Finance

Oct 08, 2026

Exelixis stock gets a higher Truist target at USD 54 - AD HOC NEWS

Oct 08, 2026

Oct 07, 2026

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

Oct 07, 2026

Exelixis (EXEL) Stock May Be Undervalued As Earnings Stay In Focus - Yahoo Finance

Oct 07, 2026

Is Exelixis Stock Engineered To Make You Money? - Yahoo Finance

Oct 07, 2026

Is Exelixis Stock Engineered To Make You Money? - Trefis

Oct 07, 2026

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

Oct 07, 2026

EXELに類似

Exelixis Inc (EXEL)

Exelixis Inc（EXEL）会社概要

EXEL と VRTX, REGN, MRNA, ARGX, ONC を比較

Exelixis Inc (EXEL) アップグレードとダウングレード

Exelixis Inc (EXEL) 財務データ

Exelixis Inc (EXEL) インサイダートレーディング

Exelixis Inc (EXEL) 最新ニュース

EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales - Zacks Investment Research

Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Zacks Investment Research

Exelixis stock hits all-time high at 65.62 USD By Investing.com - Investing.com India

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock - MarketBeat

Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight - GlobeNewswire Inc.

Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy - The Motley Fool

Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy - Yahoo Finance

Exelixis Rises with Earnings on Tap - FXEmpire

Exelixis, Inc. Estimates – NASDAQ:EXEL - TradingView

Exelixis, Inc. (EXEL) Stock forecasts - Yahoo Finance UK

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo! Finance Canada

Exelixis Faces A Test Of Its Trimmed Outlook As Street Models Run Above Guidance - Finviz

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

Exelixis Inc stock hits all-time high at 63.39 USD By Investing.com - Investing.com Nigeria

Exelixis Inc stock hits all-time high at 63.39 USD - Investing.com

EXEL Maintained by Citizens -- Price Target Raised to $65.00 - GuruFocus

Citizens raises Exelixis stock price target to $65 on ESMO data - Investing.com Canada

Exelixis, Inc. (1EXEL.MI) stock price, news, quote and history - Yahoo Finance UK

2 Under-the-Radar Stocks to Buy and Hold - The Motley Fool

Exelixis, Inc. (0IJO.IL) stock price, news, quote and history - Yahoo Finance UK

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Zacks Investment Research

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - BioSpace

Exelixis to release Q3FY26 results on Oct 29, 2026 - scanx.trade

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Yahoo Finance

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again - Zacks Investment Research

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Business Wire

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo! Finance Canada

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance Singapore

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - Morningstar

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - TradingView

Exelixis Inc stock hits all-time high at 61.21 USD - Investing.com

Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com South Africa

Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com India

Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capital - ChartMill

Virtus NFJ Mid-Cap Value Fund's Exelixis Inc(EXEL) Holding History - GuruFocus

Exelixis (NasdaqGS:EXEL) Stock Price - Simply Wall Street

Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says - marketscreener.com

RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating - Yahoo Finance

EXEL Maintained by RBC Capital -- Price Target Lowered to $45 - GuruFocus

Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus? - Yahoo Finance

Exelixis stock gets a higher Truist target at USD 54 - AD HOC NEWS

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

Exelixis (EXEL) Stock May Be Undervalued As Earnings Stay In Focus - Yahoo Finance

Is Exelixis Stock Engineered To Make You Money? - Yahoo Finance

Is Exelixis Stock Engineered To Make You Money? - Trefis

Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance

EXELに類似